High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis.
Fiche publication
Date publication
mars 2021
Journal
Clinical and translational radiation oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARTZ Nicolas
Tous les auteurs :
Martz N, Bodokh Y, Gautier M, Thamphya B, Schiappa R, Lam Cham Kee D, Chevallier D, Hannoun A, Chand ME, Hannoun-Levi JM
Lien Pubmed
Résumé
To analyze the oncological outcome and toxicity profile after conservative treatment based on multicatheter interstitial high-dose rate brachytherapy (MHB) for patients presenting a localized penile cancer.
Mots clés
ABS, American Brachytherapy Society, Brachytherapy, CCAFU, Cancer Committee of the French Association of Urology, CT, computerized tomography, CTCAE, common terminology criteria for adverse events, CTV, clinical target volume, Conservative treatment, DFS, disease-free survival, DNR, dose non-homogenity ratio, EAU, European Association of Urology, EBRT, external beam radiotherapy, EQD2, equivalent dose in 2Gy fractions, GC-SFRO, Groupe Curiethérapie/Société Française de Radiothérapie Oncologique, GEC-ESTRO, Groupe Européen de Curiethérapie/European Society for Therapeutic Radiation and Oncology, HDB, high-dose brachytherapy, IIEF, international index of erectile function, IPSS, international prostate symptom score, LC, local control, LDR, low-dose rate, MDFS, metastatic disease-free survival, MFU, median follow-up, MHB, multicatheter interstitial high-dose rate brachytherapy, MMS, Mohs micrographic surgery, MRI, magnetic resonance imaging, NCCN, national comprehensive cancer network, OS, overall survival, PDR, pulse-dose rate, PET, positron emission tomography, PP, penile preservation, Penectomy, Penile cancer, RC, regional control, SCC, squamous cell carcinoma, SFRO, Société Française de Radiothérapie Oncologique, SS, specific survival, TNM, tumor node metastasis
Référence
Clin Transl Radiat Oncol. 2021 03;27:89-95